NP118809

N-type calcium channel blocker CAS# 41332-24-5

NP118809

Catalog No. BCC1807----Order now to get a substantial discount!

Product Name & Size Price Stock
NP118809: 5mg $288 In Stock
NP118809: 10mg Please Inquire In Stock
NP118809: 20mg Please Inquire Please Inquire
NP118809: 50mg Please Inquire Please Inquire
NP118809: 100mg Please Inquire Please Inquire
NP118809: 200mg Please Inquire Please Inquire
NP118809: 500mg Please Inquire Please Inquire
NP118809: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of NP118809

Number of papers citing our products

Chemical structure

NP118809

3D structure

Chemical Properties of NP118809

Cas No. 41332-24-5 SDF Download SDF
PubChem ID 4988454 Appearance Powder
Formula C32H32N2O M.Wt 460.61
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 50 mg/mL (108.55 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Chemical Name 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one
SMILES C1CN(CCN1C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)CC(C4=CC=CC=C4)C5=CC=CC=C5
Standard InChIKey VCPMZDWBEWTGNW-UHFFFAOYSA-N
Standard InChI InChI=1S/C32H32N2O/c35-31(25-30(26-13-5-1-6-14-26)27-15-7-2-8-16-27)33-21-23-34(24-22-33)32(28-17-9-3-10-18-28)29-19-11-4-12-20-29/h1-20,30,32H,21-25H2
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

NP118809 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

NP118809 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of NP118809

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.171 mL 10.8552 mL 21.7103 mL 43.4207 mL 54.2759 mL
5 mM 0.4342 mL 2.171 mL 4.3421 mL 8.6841 mL 10.8552 mL
10 mM 0.2171 mL 1.0855 mL 2.171 mL 4.3421 mL 5.4276 mL
50 mM 0.0434 mL 0.2171 mL 0.4342 mL 0.8684 mL 1.0855 mL
100 mM 0.0217 mL 0.1086 mL 0.2171 mL 0.4342 mL 0.5428 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on NP118809

Description: IC50 Value: 0.11uM (for N-type Calcium channel) [1] NP-118809 is a potent N-type calcium channel blockers which have good selectivity over L-type calcium channels. in vitro: NP-118809, exhibited increased N-type channel blockade (IC50=0.11 uM) and was 111-fold more selective for N-type channels (L-type calcium channel IC50=12.2 uM) [1]. In the N,4-dibenzhydryl-piperazine-1-carboxamide series (21-27), non-substituted derivative (21) showed a similar inhibitory activity for N-type calcium channels (est. IC50=0.15 uM) as that of parent compound, NP-118809 (est. IC50=0.11 uM). 1-[Phenyl(pyridin-4-yl)methyl]piperazine (42), with no substituent on the nitrogen showed good N-type blocking activity (est. IC50=0.06 uM) while the N-methylated analog (43) was an order of magnitude less potent (est. IC50=0.69 uM) [2]. in vivo: NP-118809, i.v. at 2 mg/kg or p.o. at 10 mg/kg in rats, showed acceptable absorption (Tmax=2.3 hr) and half-life (2.1 hr) characteristics and a mean oral bioavailability of 30%. Both compounds were widely distributed outside of plasma and/or bound to plasma proteins. Upon i.p. administration of NP-118809 and NP-078585 at 25 mg/kg, both showed analgesic activity in Phase IIA portions of the rat formalin model. A single 1 uM dose application of NP-078585 blocked hERG currents showing its potential for cardiovascular liability [1]. Clinical trial:

Featured Products
New Products
 

References on NP118809

Scaffold-based design and synthesis of potent N-type calcium channel blockers.[Pubmed:19815411]

Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72.

The therapeutic agents flunarizine and lomerizine exhibit inhibitory activities against a variety of ion channels and neurotransmitter receptors. We have optimized their scaffolds to obtain more selective N-type calcium channel blockers. During this optimization, we discovered NP118809 and NP078585, two potent N-type calcium channel blockers which have good selectivity over L-type calcium channels. Upon intraperitoneal administration both compounds exhibit analgesic activity in a rodent model of inflammatory pain. NP118809 further exhibits a number of favorable preclinical characteristics as they relate to overall pharmacokinetics and minimal off-target activity including the hERG potassium channel.

Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors.[Pubmed:20117000]

Bioorg Med Chem Lett. 2010 Feb 15;20(4):1378-83.

A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC(50) values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain.

Description

NP118809 is a potent N-type calcium channel blocker, with an IC50 of 0.11 μM; also less potently inhibits L-type calcium channel with an IC50 of 12.2 μM.

Keywords:

NP118809,41332-24-5,Natural Products,Calcium Channel, buy NP118809 , NP118809 supplier , purchase NP118809 , NP118809 cost , NP118809 manufacturer , order NP118809 , high purity NP118809

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: